All In MedTech

Device Trial Radar · NCT01253200

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

Clinical Evaluation of the Blazer® Open-Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter

Last checked: Nov 20, 2026Latest source record: Mar 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Jan 2011

Primary completion

Sep 2013

Study completion Jan 2014

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Dec 3, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the BLOCk-CTI study is to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Ablation Catheter for the treatment of sustained or recurrent type 1 atrial flutter. This study will compare outcomes in patients treated with the Blazer® Open-Irrigated Ablation Catheter to outcomes in patients treated with open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter.

Conditions

  • Atrial Flutter

Interventions

  • Blazer® Open-Irrigated Ablation CatheterDevice

    Blazer® Open-Irrigated Ablation Catheter

  • Control CatheterDevice

    Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Procedure-related Complication-free RateTime frame: 7 days post-procedure
  2. Acute Success RateTime frame: 30 minutes after the last radiofrequency application in the cavo-tricuspid isthmus

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • St. Jude Medical Center

    Fullerton, California

  • Regional Cardiology Associates

    Sacramento, California

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.